Earnings summaries and quarterly performance for Chemomab Therapeutics.
Research analysts who have asked questions during Chemomab Therapeutics earnings calls.
Recent press releases and 8-K filings for CMMB.
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Update
CMMB
Earnings
Guidance Update
New Projects/Investments
- Chemomab Therapeutics reported a net loss of $1.7 million for the third quarter of 2025, compared to a net loss of $3.5 million for the third quarter of 2024.
- The company's cash, cash equivalents, and short-term bank deposits totaled $10.2 million as of September 30, 2025, with a projected cash runway through the end of the fourth quarter of 2026.
- Preparations for the nebokitug Phase 3 trial in primary sclerosing cholangitis (PSC) are nearing completion, with positive feedback from the FDA and EMA supporting a single registration trial using a clinical event composite endpoint.
- Research and Development (R&D) expenses decreased to approximately $1 million in the third quarter of 2025, down from $2.8 million in the third quarter of 2024, primarily due to the conclusion of Phase 2 SPRING trial activities.
Nov 21, 2025, 11:15 AM
Quarterly earnings call transcripts for Chemomab Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more